PO.TB10.13 · 肿瘤生物学
基于邻近性的基因表达谱分析鉴定出血管周围、神经周围及假包膜邻近的人类前列腺癌细胞中的多通路激活
Proximity-based gene expression profiling identifies multi-pathway activation in perivascular, perineural, and pseudo-capsule adjacent human prostate cancer cells
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
前列腺癌(PCa)进展关键地受肿瘤微环境(TME)驱动,后者施加选择性压力并支配特化的侵袭行为,如神经周围浸润和淋巴血管浸润。我们假设肿瘤内的异质性允许基于癌细胞克隆与TME生态位的邻近性对功能特化的克隆进行选择。使用空间转录组学,我们从55个人类前列腺组织数据集中对三个关键侵袭前沿——神经附近、血管附近及前列腺假包膜附近——的癌细胞群进行了谱分析。差异表达分析揭示了独特的、生态位特异性的功能特征:神经附近的嗜神经克隆表现出前列腺身份的丧失和神经黏附基因的获得(如NCAM1、NTN1),与神经周围浸润一致;血管周围克隆显示ECM重塑的上调及EMT样状态(如ANXA2、CCN1),提示为血管内渗做准备;而假包膜邻近的克隆则表现出高度增殖的表型(如CCND1、CDK4)。这些结果表明TME驱动PCa细胞的功能特化,深化了我们对侵袭的理解,并提名若干生态位特异性通路作为潜在治疗靶点。目前正在进行研究以验证这些特征、优化异质性评分,并将所鉴定基因与药理学数据库交叉关联,用于未来的体外抑制实验。
查看英文原文 English abstract
Prostate cancer (PCa) progression is critically driven by the tumor microenvironment (TME), which imposes selective pressures and dictates specialized invasive behaviors, such as perineural and lymphovascular invasion. We hypothesized that heterogeneity within the tumor allows for the selection of functionally specialized cancer cell clones based on their proximity to TME niches. Using Spatial Transcriptomics, we profiled cancer cell populations at three critical invasive fronts: near nerves, vessels, and the prostatic pseudo-capsule from 55 human prostate tissue datasets. Differential expression analysis revealed distinct, niche-specific functional signatures: neurotropic clones near nerves exhibited a loss of prostate identity and a gain of neural adhesion genes (e.g., NCAM1, NTN1) consistent with perineural invasion; perivascular clones showed upregulation of ECM remodeling and an EMT-like state (e.g., ANXA2, CCN1), suggesting priming for intravasation; and pseudo-capsule-adjacent clones displayed a highly proliferative phenotype (e.g., CCND1, CDK4). These results demonstrate that the TME drives the functional specialization of PCa cells, refining our understanding of invasion and nominating several niche-specific pathways as potential therapeutic targets. Studies are currently ongoing to validate these signatures, refine heterogeneity scoring, and cross-link the identified genes with pharmacological databases for future in-vitro inhibition assays.
利益披露 Disclosure
R. Sainz,
Roche Tissue Diagnostics Employment.
K. W. Pond, None..
G. C. Rogers, None..
N. E. Warfel, None..
A. E. Cress, None.